MiR-130a acts as a potential diagnostic biomarker and promotes gastric cancer migration, invasion and proliferation by targeting RUNX3

Oncology Reports

Volumn 34, Issue 3, 2015, Pages 1153-1161

  Jiang, Hong ^a   Yu, Wei Wei ^a   Wang, Lu Lu ^b   Peng, Yang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Diagnosis; Gastric cancer; MiR 130a; Prognosis; RUNX3; Tumorigenesis

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MICRORNA; MICRORNA 130A; SMAD4 PROTEIN; TRANSCRIPTION FACTOR RUNX3; TUMOR MARKER; UNCLASSIFIED DRUG; MIRN130 MICRORNA, HUMAN; RUNX3 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; MTT ASSAY; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; STOMACH CARCINOGENESIS; UPREGULATION; VERY ELDERLY; BIOSYNTHESIS; CELL MOTION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IMMUNOBLOTTING; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TUMOR INVASION;

AREA UNDER CURVE; BIOMARKERS, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CORE BINDING FACTOR ALPHA 3 SUBUNIT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; KAPLAN-MEIER ESTIMATE; MICRORNAS; NEOPLASM INVASIVENESS; ONCOGENES; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; ROC CURVE; STOMACH NEOPLASMS; TRANSFECTION; UP-REGULATION;

EID: 84937214096     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4099     Document Type: Article

References (42)

1. Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet 374: 477-490, 2009.
2. K amangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
3. Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J and Sung JJ: MicroRNA dysregulation in gastric cancer: A new player enters the game. Oncogene 29: 5761-5771, 2010.
4. Rana TM: Illuminating the silence: Understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 8: 23-36, 2007.
5. Valencia-Sanchez MA, Liu J, Hannon GJ and Parker R: Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20: 515-524, 2006.
6. Pillai RS, Bhattacharyya SN and Filipowicz W: Repression of protein synthesis by miRNAs: How many mechanisms? Trends Cell Biol 17: 118-126, 2007.
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
8. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T and Hammond SM: Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 20: 2202-2207, 2006.
9. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
10. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
11. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425-436, 2008.
12. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, et al: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111: 3183-3189, 2008.
13. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, et al: Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50: 136-142, 2011.
14. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N and Gezer U: Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 32: 583-588, 2011.
15. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-675, 2008.
16. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM and Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112: 55-59, 2009.
17. Qiu S, Lin S, Hu D, Feng Y, Tan Y and Peng Y: Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med 11: 10, 2013.
18. Ratert N, Meyer HA, Jung M, Lioudmer P, Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert S, et al: miRNA profiling identifies candidate miRNAs for bladder cancer diagnosis and clinical outcome. J Mol Diagn 15: 695-705, 2013.
19. I shihara K, Sasaki D, Tsuruda K, Inokuchi N, Nagai K , Hasegawa H, Yanagihara K and Kamihira S: Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol 36: 560-565, 2012.
20. Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, Altmeyer P and Bechara FG: Expression of microRNAs in basal cell carcinoma. Br J Dermatol 167: 847-855, 2012.
21. Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ, Wang TY, Li HC and Wu XN: Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett 5: 1639-1642, 2013.
22. Zhang X, Huang L, Zhao Y and Tan W: Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. Acta Biochim Biophys Sin 45: 995-1001, 2013.
23. Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q and Zhang J: Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun 425: 468-472, 2012.
24. Huang B, Qu Z, Ong CW, Tsang YH, Xiao G, Shapiro D, Salto-Tellez M, Ito K, Ito Y and Chen LF: RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α. Oncogene 31: 527-534, 2012.
25. K im WJ, Kim EJ, Jeong P, Quan C, Kim J, Li QL, Yang JO, Ito Y and Bae SC: RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 65: 9347-9354, 2005.
26. Araki K, Osaki M, Nagahama Y, Hiramatsu T, Nakamura H, Ohgi S and Ito H: Expression of RUNX3 protein in human lung adenocarcinoma: Implications for tumor progression and prognosis. Cancer Sci 96: 227-231, 2005.
27. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, et al: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124, 2002.
28. Hsu PI, Hsieh HL, Lee J, Lin LF, Chen HC, Lu PJ and Hsiao M: Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer. Ann Surg Oncol 16: 1686-1694, 2009.
29. K undu J, Wahab SM, Kundu JK, Choi YL, Erkin OC, Lee HS, Park SG and Shin YK: Tob1 induces apoptosis and inhibits proliferation, migration and invasion of gastric cancer cells by activating Smad4 and inhibiting β-catenin signaling. Int J Oncol 41: 839-848, 2012.
30. Fukamachi H: Runx3 controls growth and differentiation of gastric epithelial cells in mammals. Dev Growth Differ 48: 1-13, 2006.
31. Cheng HC, Liu YP, Shan YS, Huang CY, Lin FC, Lin LC, Lee L, Tsai CH, Hsiao M and Lu PJ: Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer. Carcinogenesis 34: 2452-2459, 2013.
32. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung K: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-1176, 2010.
33. Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS, Chang I, Yamamura S, Chiyomaru T, Fukuhara S, et al: MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One 7: e46743, 2012.
34. Gotoda T, Yamamoto H and Soetikno RM: Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol 41: 929-942, 2006.
35. K osuke N, Oguma H and Yamamoto M: Early gastric cancer with lymph node metastasis. Ann Surg 253: 840-841, 2011.
36. K im BS, Cho SW, Min SK and Lee BH: Differences in prognostic factors between early and advanced gastric cancer. Hepatogastroenterology 58: 1032-1040, 2011.
37. Lai IR, Lee WJ, Huang MT and Lin HH: Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 49: 1157-1160, 2002.
38. Gao F, Chang J, Wang H and Zhang G: Potential diagnostic value of miR-155 in serum from lung adenocarcinoma patients. Oncol Rep 31: 351-357, 2014.
39. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J and Li J: Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 7: e47003, 2012.
40. Chu Y, Ouyang Y, Wang F, Zheng A, Bai L, Han L, Chen Y and Wang H: MicroRNA-590 promotes cervical cancer cell growth and invasion by targeting CHL1. J Cell Biochem 115: 847-853, 2014.
41. Ma Y, Qin H and Cui Y: miR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway. Biochem Biophys Res Commun 441: 958-963, 2013.
42. Meng S, Cao J, Zhang X, Fan Y, Fang L, Wang C, Lv Z, Fu D and Li Y: Downregulation of microRNA-130a contributes to endothelial progenitor cell dysfunction in diabetic patients via its target Runx3. PLoS One 8: e68611, 2013.